Delamanid for multidrug-resistant pulmonary tuberculosis.

  title={Delamanid for multidrug-resistant pulmonary tuberculosis.},
  author={Maria Tarcela S. Gler and Vija Skripconoka and Epifanio Sanchez-Garavito and He-ping Xiao and Jose L Cabrera-Rivero and Dante E Vargas-Vasquez and Mengqiu Gao and Mohamed Hammam Awad and Seung-Kyu Park and Tae Sun Shim and Gee Young Suh and Manfred Danilovit{\vs} and Hideo Ogata and Anu Kurve and Joon Chang and Katsuhiro Suzuki and Thelma E. Tupasi and Won-jung Koh and Barbara Joyce Seaworth and Lawrence J. Geiter and Charles D. Wells},
  journal={The New England journal of medicine},
  volume={366 23},
BACKGROUND Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis. METHODS In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly all of whom were negative for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Highly Cited
This paper has 243 citations. REVIEW CITATIONS


Publications citing this paper.
Showing 1-10 of 222 citations

243 Citations

Citations per Year
Semantic Scholar estimates that this publication has 243 citations based on the available data.

See our FAQ for additional information.


Publications referenced by this paper.
Showing 1-10 of 14 references